FDA Flags Novo Nordisk Over Side-Effect Reporting; Death Lawsuit Filed Over Ozempic

Novo Nordisk, maker of Ozempic and Wegovy, faces scrutiny after the FDA accused the company of failing to properly report serious side effects, including deaths and strokes, linked to semaglutide-based drugs. The FDA's warning letter cites potential systemic failures in adverse event reporting. Concurrently, a US family filed a lawsuit alleging a death caused by stomach paralysis after Ozempic use. These developments highlight ongoing concerns about the safety monitoring of GLP-1 receptor agonists widely prescribed for diabetes and weight management.